The company plans to sell 9 million shares at $19.00 per share, which is expected to bring in $171.0 million in gross proceeds.
Invitae hasn't priced the offering yet or disclosed how many shares it will offer, but it expects net proceeds to range from $117.1 million to $134.7 million.
In an SEC document, the company said net proceeds are expected to be $5.8 million and will be used to support an anticipated submission to the FDA, among other things.
The company's revenues in the quarter rose to $221.9 million from $161.0 million in Q4 2017, but it missed the consensus Wall Street estimate of $245.3 million.
Biocept is offering 6.25 million shares of its common stock and warrants to purchase up to 6.25 million shares of the common stock at a combined price $1.20 per share and warrant.
Both Opko and Phillip Frost will pay penalties and refrain from certain activities. Frost had been accused by the SEC of participating in market manipulation schemes.
The company was hit with an SEC lawsuit last week and said it expects the Nasdaq matter to be "resolved favorably" but it cannot estimate when trading will resume.
In its response, the company accused the Securities and Exchange Commission's lawsuit of containing "serious factual inaccuracies."
The company also entered into a sales agreement with Cowen and Company to offer up to $75 million of its common stock for sale.